Richard C. Mulligan

Richard C. Mulligan, Ph.D., (born 1954) is the Mallinckrodt Professor of Genetics at Harvard Medical School,[1][2][3] and Director of the Harvard Gene Therapy Initiative.[4]

He is a Director of Enzon Pharmaceuticals, Inc.,[5] and Biogen Idec, Inc..[6]

Awards

Works

References

  1. "Richard C. Mulligan, Ph.D. | HMS Department of Genetics". genetics.med.harvard.edu. Retrieved 2016-06-21.
  2. http://www.hms.harvard.edu/dms/bbs/fac/mulligan.html
  3. "Richard C. Mulligan, Ph.D. - DF/HCC". dfhcc.harvard.edu. Retrieved 2016-06-21.
  4. "Forbes Welcome | "Richard C. Mulligan"". people.forbes.com. Retrieved 2016-06-21.
  5. "Enzon". enzon.com. Retrieved 2016-06-21.
  6. "Business Briefing / Biotechnology - latimes". articles.latimes.com. Retrieved 2016-06-21.
  7. "Searle Scholars Program : Richard C. Mulligan (1983)". searlescholars.net. Retrieved 2016-06-21.

External links

This article is issued from Wikipedia - version of the 6/21/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.